Primenenie zomety v lechenii metastaticheskogo porazheniya skeleta (klinicheskiy opyt)
- Authors: Aliev MD1, Bolotina LV2, Teplyakov VV1, Koroleva LA2, Karpenko VY.1, Titov DA1
-
Affiliations:
- РОНЦ им. Н.Н.Блохина РАМН
- МНИОИ им. П.А.Герцена
- Issue: Vol 6, No 3 (2004)
- Pages: 113-116
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/26552
- ID: 26552
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
M D Aliev
РОНЦ им. Н.Н.Блохина РАМН
L V Bolotina
МНИОИ им. П.А.Герцена
V V Teplyakov
РОНЦ им. Н.Н.Блохина РАМН
L A Koroleva
МНИОИ им. П.А.Герцена
V Yu Karpenko
РОНЦ им. Н.Н.Блохина РАМН
D A Titov
РОНЦ им. Н.Н.Блохина РАМН
References
- Daniell H.W, Dunn S.R, Ferguson D.W et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 163: 181-6.
- Sahni M,Guenther H, Collin P et al. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993; 91: 2004-11.
- Jagdev S.P, Coleman R.E, Shipman S.M et al. The bisphosphonate, zoledronic acid, induced apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001, Apr 20; 84 (8): 1126-34.
- Corey E, Brown L.G, Quinn J.E et al. Effects of zoledronic acid on prostate cancer in vitro and in vivo. 92nd Annu Meet Am Assoc Cancer Res 2001 Mar; 42: 214.
- Rosen L.S, Gordon D, Kaminski M et al. Long - term efficacy and safety of zoledronic acid compared with pamidronate disodium in the trearment of skeletal complication in patient with advanced multiple mieloma or breast carcinoma. Cancer 2003; 98: 1735-44.
- Bruce E Hillner, James N. Ingle, Roman T. Chlebowski, Julie Gralow et all. Americam Society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol November 1, 2003; 21 (21).